お知らせ
2018.05.11
医療関係者
第70回日本産科婦人科学会学術集会が開催されます」 2017.5.10-13
平成30年5月11日 (金)
松野香苗先生
ISP-25-4 A study to evaluate the impact of surgical menopause on bone metabolism in women below 50 years of age
田畑潤哉先生
ISP-7-7 A Machine Learning Algorithm Using Blood Biomarkers for Diagnostic and Prognostic in Epithelial Ovarian Cancer
平田幸広先生
ISP-1-8 The clinicopathological characteristics and PD-L1 expression in neuroendocrine carcinoma of the cervix
宇田川治彦先生
ISP-49-6 Postnatal depression associated with pregnancy induced by assisted reproductive technology
薮崎恵子先生
ISP-20-3 Analgesic effect of regular intravenous administration of acetaminophen for pain due to post-cesarean delivery : a retrospective study
笠原佑太先生
ISP-30-4 Evaluation of fertility preservation in 25 patients with hematologic malignancies at our hospital
坂本優先生
ISP-36-3 Phase I/IIa study of photodynamic therapy using talaporfin sodium and diode laser(L-PDT) for Cervical Intraepithelial Neoplasia
斎藤良介先生
ISP-40-10 Identification of Potential Biomarkers of recurrent advanced ovarian cancer during bevacizumab maintenance therapy as part of first-line treatment
松野香苗先生
ISP-25-4 A study to evaluate the impact of surgical menopause on bone metabolism in women below 50 years of age
田畑潤哉先生
ISP-7-7 A Machine Learning Algorithm Using Blood Biomarkers for Diagnostic and Prognostic in Epithelial Ovarian Cancer
平田幸広先生
ISP-1-8 The clinicopathological characteristics and PD-L1 expression in neuroendocrine carcinoma of the cervix
宇田川治彦先生
ISP-49-6 Postnatal depression associated with pregnancy induced by assisted reproductive technology
薮崎恵子先生
ISP-20-3 Analgesic effect of regular intravenous administration of acetaminophen for pain due to post-cesarean delivery : a retrospective study
笠原佑太先生
ISP-30-4 Evaluation of fertility preservation in 25 patients with hematologic malignancies at our hospital
坂本優先生
ISP-36-3 Phase I/IIa study of photodynamic therapy using talaporfin sodium and diode laser(L-PDT) for Cervical Intraepithelial Neoplasia
斎藤良介先生
ISP-40-10 Identification of Potential Biomarkers of recurrent advanced ovarian cancer during bevacizumab maintenance therapy as part of first-line treatment
